NDA Submitted for Avanafil for Erectile Dysfunction
Vivus announced that a New Drug Application (NDA) has been submitted to the FDA for avanafil for the treatment of erectile dysfunction (ED). The NDA submission follows the successful completion of an extensive Phase 3 study for avanafil, which included over 1,350 patients, where avanafil was shown to be well tolerated and effective in treating men with ED.
Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor taken orally for the treatment of ED.
For more information call (650) 934-5200 or visit www.vivus.com.